使用现实世界的证据调查多发性骨髓瘤患者的CAR-T治疗准入
Jaysón Davidson1,2, Anupama Kumar3, Ayan Patel2
1Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA 94158, USA.
Cancers
|February 27, 2026
概括
多发性骨髓瘤 (MM) 的黑人患者接受CAR-T治疗的几率较低. 一些符合条件的患者缺乏记录的CAR-T治疗讨论,这表明护理途径的潜在差异.
科学领域:
- 血液学恶性瘤 血液学恶性瘤
- 免疫治疗是一种免疫疗法.
背景情况:
- 多发性骨髓瘤 (MM) 是一种严重的血液性恶性瘤,在黑人患者中发病率较高.
- 化学抗原受体T细胞 (CAR-T) 疗法具有前景,但面临着难以获得的挑战.
研究的目的:
- 调查MM患者接受CAR-T治疗的相关因素.
- 检查疾病特征,治疗地点和人口统计学对CAR-T疗法的影响.
主要方法:
- 使用电子健康记录 (2021-2025) 对12360名MM患者进行回顾性队列研究.
- 后勤回归分析了人口统计,疾病阶段和CAR-T接收之间的关联.
- 零射击GPT-4模型从临床笔记中评估了CAR-T讨论和资格.
主要成果:
- 只有2.6%的MM患者接受了CAR-T治疗.
- 与白人患者相比,黑人患者接受CAR-T治疗的几率明显较低 (OR 0.33).
- 在符合条件的患者中,在种族群体之间观察到记录的CAR-T讨论中的差异.
结论:
- 在MM中接受CAR-T治疗的情况因治疗地点和患者种族而异,在一个大型医疗系统内不同.
- 在转诊,文档或护理途径的潜在差异可能会影响某些患者群体的CAR-T治疗机会.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.9K
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
54.2K
相关概念视频
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Cancer Survival Analysis
805
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
805
